• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

First Wave BioPharma, Inc. - Common Stock (NQ:FWBI)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about First Wave BioPharma, Inc. - Common Stock

Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
January 05, 2024
Via AB Newswire
News headline image
First Wave BioPharma (NASDAQ: FWBI) Makes Significant Progress in Phase 2 SPAN Clinical Trial
June 13, 2023
Trial Enrollment Completed for Investigational Therapy of Exocrine Pancreatic Insufficiency First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company 
Via Spotlight Growth
News headline image
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
March 13, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
First Wave BioPharma, Inc. (NASDAQ: FWBI) Featured in Coverage of the 35th Annual Roth Conference
February 17, 2023
Via Investor Brand Network
First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results Expected 1H/2023 ($FWBI)
December 01, 2022
Via AB Newswire
First Wave BioPharma’s Reformulated Adrulipase Targets Front Line Position Treating Certain Exocrine Pancreatic Insufficiency ($FWBI)
October 13, 2022
Via AB Newswire
News headline image
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews James Sapirstein CEO, First Wave BioPharma, Inc.
October 06, 2022
Via ACCESSWIRE
First Wave BioPharma Stock Bid Higher After Adrulipase Study Update; Expects To File IND Application In Q4 ($FWBI)
September 27, 2022
Via AB Newswire
First Wave BioPharma Earns $16 PT From Goldman SCR; Expects 1691% Surge As 2021 Milestones Become 2022 Catalysts ($FWBI)
March 31, 2022
Via AB Newswire
First Wave BioPharma, Inc. (NASDAQ: FWBI) Featured in Virtual Coverage of the 34th Annual Roth Conference
March 07, 2022
Via Investor Brand Network
First Wave BioPharma’s Fast-Tracked Phase 2 Candidate To Treat COVID-RELATED GI Tract Infection Gives Hope To Millions (NASDAQ: FWBI)
March 02, 2022
Via AB Newswire
First Wave BioPharma On Track For Transformational 2022, EUA And Phase-2 COVID-Related GI Trial Data In Focus (NASDAQ: FWBI)
February 17, 2022
Via AB Newswire
With Full Enrollment Complete In Its Phase 2 COVID-Related GI Treatment Trial, First Wave Bio Could Earn An EUA Sooner Than Later (NASDAQ: FWBI)
January 11, 2022
Via AB Newswire
A Deeper Dive Into AzurRx BioPharma’s Acquisition Of First Wave Bio; Low Up-Front Terms Are Very Shareholder Friendly (NASDAQ: FWBI)
October 20, 2021
Via AB Newswire
First Wave BioPharma Initiates Phase2b Trial Targeting Unmet Treatment For Ulcerative Proctitis And UPS; Adds To Growing List Of 2021 Milestones (NASDAQ: FWBI)
October 18, 2021
Via AB Newswire
First Wave BioPharma Launched: AzurRx BioPharma and First Wave Bio Merge To Target Billion Dollar GI and IBD Treatment Markets (NASDAQ: FWBI)
September 28, 2021
Via AB Newswire
First Wave Bio And AzrurRx BioPharma Combine To Target Billion Dollar GI and IBD Treatment Market; Completes Massive $229 Million Deal (NASDAQ: FWBI)
September 27, 2021
Via AB Newswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap